THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

FDA issues Boston Scientific stern quality-control warning

By Stephen Heuser
Globe Staff / January 27, 2006

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

(Correction: Because of a reporting error, stories on Boston Scientific Corp.'s acquisition of Guidant Corp. in the Jan. 24, 25, and 27 Business sections contained an incorrect figure for the minimum price Boston Scientific stock must maintain to keep the deal's value from decreasing for Guidant shareholders. The share price must remain at $22.62 or higher.) (Full article: 713 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass